Pharmaceuticals
Ascletis Announces U.S. IND Approval of Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors
* The objectives of the U.S. Phase I trial are to find a recommended Phase II dose and obtain preliminary efficacy in patients with advanced solid tumors * The first U.S. patient is expected to be dosed in the first half of 2022 * ASC61 shows significant antitumor efficacy as a single agent i...
2022-02-06 18:30
4147
Vitro S.A. sells Cytognos to BD to prioritize the market launch of their new and disruptive Molecular Biology and Anatomic Pathology diagnostic platforms
Cytognos divestment is a first strategic step aimed at positioning Vitro as a
new worldwide diagnostic player in their key market segments
SEVILLE, Spain, Feb. 4, 2022 /PRNewswire/ -- Vitro S.A, (www.vitro.bio
2022-02-04 17:23
4343
Nanoform signs GMP manufacturing program with TargTex following formulation success
HELSINKI, Feb. 4, 2022 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, today announced it has signed a GMP1 manufacturing program (clinical development) to enhance TargTex's Glioblastoma multiforme drug candidate. The program starts with a PoP (Proof of Process) ph...
2022-02-04 15:54
3178
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
Nuvaxovid™ is the first protein-based COVID-19 vaccine to receive provisional approval for distribution inNew Zealand GAITHERSBURG, Md., Feb. 4, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for ser...
2022-02-04 06:54
2576
Mentice publishes the company's year-end report for the period January-December 2021
STOCKHOLM, Feb. 3, 2022 /PRNewswire/ -- Continued strength with net sales growth above 30% despite the pandemic Fourth quarter (October-December 2021) * Order intake amounted to 73.7 (73.1) MSEK. * Net sales amounted to 67.7 (45.9) MSEK. * Operating income for the period before depreciation...
2022-02-03 15:37
2176
CordenPharma Completes Acquisition of Three Manufacturing Facilities from Vifor Pharma
LUXEMBOURG, Feb. 2, 2022 /PRNewswire/ -- CordenPharma, a leading, full-service Contract Development & Manufacturing Organization (CDMO) supplying APIs, Excipients, Drug Products, and associated Packaging services, announced today the completion of the acquisition of three manufacturing facilities...
2022-02-02 11:00
2955
World's most trusted source for chemistry information, CAS, launches major biology expansion
CAS SciFinder Discovery Platform™ redefines its role in drug discovery with the inclusion of unique biosequence data collection and capabilities COLUMBUS, Ohio, Feb. 2, 2022 /PRNewswire/ -- CAS, a division of the American Chemical Society specializing in scientific information solutions, announce...
2022-02-02 10:42
2811
New Business Partnership Between Otsuka Pharmaceutical and Digital Health VR Technology Developer Jolly Good
TOKYO, Feb. 1, 2022 /PRNewswire/ -- With the aim of building a regional cooperative mental health platform, Jolly Good Inc. (Chuo-ku,Tokyo; CEO: Kensuke Joji) and Otsuka Pharmaceutical Co., Ltd. (Chiyoda-ku, Tokyo; President and Representative Director:Makoto Inoue) have signed an agreement for ...
2022-02-01 21:00
2177
Cytiva fuels biotech development in Australia and New Zealand
* VivaZome Therapeutics wins top prize with its potential to provide off-the-shelf regenerative medicines. * Part of Cytiva's BioChallenge global series, the inaugural challenge for the Australia and New Zealand region received 32 applications from various universities and companies. SYDNEY, F...
2022-02-01 07:00
2978
DEBIOPHARM AND ASPEN PARTNER TO LAUNCH PROSTATE CANCER DRUG TRELSTAR® IN SOUTH AFRICA
LAUSANNE, Switzerland and DURBAN, South Africa, Feb. 1, 2022 /PRNewswire/ --
Debiopharm (www.debiopharm.com
2022-02-01 06:00
3174
Denovo Biopharma LLC Announces FDA Approval of IND to Initiate First Biomarker-Guided Global CNS Clinical Trial for Treatment-Resistant Depression (TRD)
SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- Denovo Biopharma LLC ("Denovo"), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the FDA has authorized the company's investigational new drug (IND) application of DB104 (liafensine) for treatment-r...
2022-02-01 05:30
2387
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
- NVX-CoV2373 demonstrated overall efficacy of ~90% in PREVENT-19 clinical trial conducted during the emergence of variant strains GAITHERSBURG, Md., Feb. 1, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vac...
2022-02-01 04:06
3437
Exopharm and Astellas Institute for Regenerative Medicine (AIRM) Sign Master Collaborative Services Agreement
* Astellas Institute for Regenerative Medicine (AIRM) is a subsidiary of Astellas Pharma Inc., a top 20 global pharmaceutical company * Initial services will seek to validate Exopharm's LEAP, LOAD and EVPS technology platforms to manufacture exosomes for Astellas, firstly at Exopharm's facili...
2022-01-31 19:00
1694
HanBio Therapeutics Announces the Completion of a US$40 Million Series A Financing Led by OrbiMed and Hankang Capital
SHANGHAI, Jan. 28, 2022 /PRNewswire/ -- HanBio Therapeutics ("HanBio"), a biotechnology company committed to researching and developing next generation transformative medicines, today announced that it has completed aUS$40 million Series A financing to advance the preclinical and clinical develop...
2022-01-29 11:37
6826
Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China
BASEL, Switzerland, KUOPIO, Finland, and SHENZHEN, China, Jan. 29, 2022 /PRNewswire/ -- Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two compan...
2022-01-29 05:28
4127
CTB001, Bioheng auto CAR - T Product, received Orphan Drug Designation (ODD) from the U.S. FDA
NANJING, China, Jan. 28, 2022 /PRNewswire/ -- Recently, Nanjing Bioheng Biotech Co.,Ltd. ( hereinafter referred to as Bioheng) announced that its anti-claudin 18.2 autologous CAR-T cell therapy product CTB001 received Orphan Drug Designation (ODD) from the Food and Drug Administration (FDA) for t...
2022-01-28 22:00
2892
I-Mab Announces Partnership Agreement to Localize Manufacturing and Accelerate Commercialization of Innovative Biologics Drugs
SHANGHAI and GAITHERSBURG, Md., Jan. 28, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, announced the signing of a partnership agreement with the Hangzhou Qian...
2022-01-28 21:00
2531
Samsung Biologics reaches agreement with Biogen to acquire full ownership of Samsung Bioepis
* Agreement with Biogen to buyout Biogen's (50% -1 share) stake in Samsung Bioepis Joint Venture for up to USD$2.3 billion * Transaction projected to be accretive to earnings in 2022 and thereafter, fully capitalizing on the high growth potential of Samsung Bioepis * Expected to accelerate g...
2022-01-28 08:10
1899
Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform
NANTONG, China, Jan. 27, 2022 /PRNewswire/ -- Ractigen Therapeutics, a pioneer of the RNAa technology, today announced the closing of a Series A+ financing round totaling$30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital...
2022-01-27 22:10
1905
FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion
SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation toDZD9008 (Sunvozertinib) for the treatment of patients with locally advanced or metasta...
2022-01-27 21:15
3665
Week's Top Stories
Most Reposted
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
[Picked up by 337 media titles]
2025-01-18 03:30
Supported by the Luxembourg Government, The Luxembourg House of Financial Technology (LHoFT) and the Asian Development Bank (ADB) Announce the 2nd Edition of Catapult | SE Asia 2025
[Picked up by 313 media titles]
2025-01-22 15:38
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
[Picked up by 311 media titles]
2025-01-18 17:00
dss⁺ Announces Strategic Changes to Executive Leadership Team in Asia Pacific Accelerating growth and impact for high-hazard industries in the region
[Picked up by 309 media titles]
2025-01-21 16:00
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
[Picked up by 306 media titles]
2025-01-20 14:27
Most Read
LONG AN INTERNATIONAL PORT JOINS 12TH PORTECH ASIA SUMMIT 2025 IN MALAYSIA
2025-01-18 03:30
12403
Hong Kong Airlines Takes Off to Australia's Gold Coast Bringing Popular Travel Option for the Chinese New Year
2025-01-18 17:00
11608
EZGO ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2024
2025-01-18 06:45
8656
MONTECH Debuts the Heritage: A New Era of Leather Craft & High-End PC
2025-01-18 22:00
5442
HARD ROCK HOTEL BALI ACHIEVES PRESTIGIOUS GSTC CERTIFICATION
2025-01-20 14:27
4747